Clinical Trials
3
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- CABYC
- Target Recruit Count
- 34
- Registration Number
- NCT00781781
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸ICO Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital Clinic i Provincial., Barcelona, Cataluña, Spain
Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2012-01-02
- Lead Sponsor
- CABYC
- Target Recruit Count
- 30
- Registration Number
- NCT00505232
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Marques de Valdecilla, Santander, Cantabria, Spain
🇪🇸Hospital del Mar, Barcelona, Cataluña, Spain
R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia
Phase 2
Withdrawn
- Conditions
- Chronic Lymphocytic LeukaemiaPatients Resistant to a Purine AnalogousPatients Relapsed With Purines Therapy
- Interventions
- Drug: Rituximab-CHOP-Alemtuzumab
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2011-12-30
- Lead Sponsor
- CABYC
- Registration Number
- NCT00504491
- Locations
- 🇪🇸
ICO Badalona, Badalona, Barcelona, Spain
🇪🇸ICO Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Althaia, Manresa, Barcelona, Spain
News
No news found